Login Register Cart 0
Generic placeholder image

Current Enzyme Inhibition

Editor-in-Chief

ISSN (Print): 1573-4080
ISSN (Online): 1875-6662

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

In Silico Design, Synthesis and Evaluation of Hydroxyxanthone Derivatives as Potential Anti-diabetic Agents Targeting α-glucosidase

Author(s): Riya Saikia*, Aparoop Das, Kalyani Pathak, Neelutpal Gogoi, Tirna Paul, Jon Jyoti Sahariah and Himangshu Sarma

Volume 18, Issue 3, 2022

Published on: 21 October, 2022

Page: [211 - 225] Pages: 15

DOI: 10.2174/1573408018666220627114552

Price: $65

Abstract

Background: Glucosidase is a catalytic enzyme that catalyzes, specifically hydrolyses, the carbohydrates to free glucose units in blood in the last step of carbohydrate metabolism. So far, many compounds with α-glucosidase inhibitory activity, for example, acarbose, voglibose etc., have been accounted and commercialized for diabetes therapy. However, xanthones are recognized as efficient glucosidase inhibitors because of their planar structure, and have opened the door for the researchers to utilize the same for designing and developing potent and novel hybrid xanthones for anti-diabetic therapy.

Objectives: The current study aimed to determine and evaluate the anti-diabetic potential of different synthetic hydroxylxanthone derivatives using Nicotinamide and Streptozotocin (60mg/kg i.p.) induced diabetic rats.

Methods: The partially purified synthetic hydroxyxanthone derivatives, namely A1, A2, A3, A4, and A5, were administered to diabetic rats at a dose of 150mg/kg per oral(p.o.), and the effect of the fraction on blood glucose level was studied for up to 21 days. Further, the synthetic compounds were subjected to spectral analysis for their characterization.

Results: The in silico molecular docking results indicated that compound A3 has shown the best binding energy score. Also, the in vivo anti-diabetic potential of the synthetic hydroxyxanthone derivatives has revealed the compounds A3 and A2 to be significantly effective in controlling the blood glucose level when compared to the standard drug miglitol. In addition, compounds A3 and A2 were found to be effective in restoring the enzymes of the liver and lipid profile in Streptozotocin-induced Wistar rat models.

Conclusion: With an objective to investigate the compounds for predicting biological activity, it was found that the hydroxyxanthone possesses a safety margin for toxicity and acts as a lead toward the development of potential α-glucosidase inhibitors. These compounds show an excellent correlation between docking results, synthetic data and in vivo anti-diabetic activity. However, further modifications can be done to enhance the potency and binding affinity profile, and minimize toxicity.

Keywords: α-glucosidase, xanthone, hydroxyxanthone, diabetesmellitus, Streptozotocin, miglitol

« Previous Next »
Graphical Abstract

[1]
Cardona ML, Fernandez I, Pedro JR, Serrano A. Xanthones from hypericumreflexum. Phytochemistry 1990; 29(9): 3003-6.
[http://dx.doi.org/10.1016/0031-9422(90)87123-C]
[2]
Hostettmann K, Miura I. A new Xanthonediglucoside from Swertiaperennis L. Helv Chim Acta 1977; 60(1): 262-4.
[http://dx.doi.org/10.1002/hlca.19770600133]
[3]
Footie J, Bohle DS. Pharmacological and biological activities of xanthones. Antiinfect Agents Med Chem 2006; 5(1): 15-31.
[http://dx.doi.org/10.2174/187152106774755563]
[4]
Poitout V, Robertson RP. Glucolipotoxicity: fuel excess and beta-cell dysfunction. Endocr Rev 2008; 29(3): 351-66.
[http://dx.doi.org/10.1210/er.2007-0023] [PMID: 18048763]
[5]
Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54(6): 1615-25.
[http://dx.doi.org/10.2337/diabetes.54.6.1615] [PMID: 15919781]
[6]
Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414(6865): 813-20.
[http://dx.doi.org/10.1038/414813a] [PMID: 11742414]
[7]
Calcutt NA, Cooper ME, Kern TS, Schmidt AM. Therapies for hyperglycaemia-induced diabetic complications: From animal models to clinical trials. Nat Rev Drug Discov 2009; 8(5): 417-29.
[http://dx.doi.org/10.1038/nrd2476] [PMID: 19404313]
[8]
Chaudhury A, Dufour C, Kraleti VSRDS, et al. Clinical review of anti-diabetic drugs: Implications for type 2 diabetes mellitus management. Front Endocrinol (Lausanne) 2017; 8: 12.
[http://dx.doi.org/10.3389/fendo.2017.00006]
[9]
Liu Z, Ma S. Recent advances in synthetic a-glucosidase inhibitors. ChemMedChem 2017; 12(11): 819-29.
[http://dx.doi.org/10.1002/cmdc.201700216] [PMID: 28498640]
[10]
Abid S, Berraaouan A, Bnouham M. Natural alpha-glucosidase inhibitors: Therapeutic implication and structure-activity relationship. Lett Drug Des Discov 2016; 7(7): 605-37.
[http://dx.doi.org/10.2174/1570180812666150918193508]
[11]
Kasturi SP, Surarapu S, Uppalanchi S, et al. Synthesis, molecular modeling and evaluation of α-glucosidase inhibition activity of 3,4-dihydroxy piperidines. Eur J Med Chem 2018; 150: 39-52.
[http://dx.doi.org/10.1016/j.ejmech.2018.02.072] [PMID: 29518717]
[12]
Kasturi S, Surarapu S, Uppalanchi S, et al. Synthesis and α-glucosidase inhibition activity of dihydroxy pyrrolidines. Bioorg Med Chem Lett 2017; 27(12): 2818-23.
[http://dx.doi.org/10.1016/j.bmcl.2017.04.078] [PMID: 28495082]
[13]
Proença C, Freitas M, Ribeiro D, et al. α-Glucosidase inhibition by flavonoids: An in vitro and in silico structure-activity relationship study. J Enzyme Inhib Med Chem 2017; 32(1): 1216-28.
[http://dx.doi.org/10.1080/14756366.2017.1368503] [PMID: 28933564]
[14]
Heightman TD, Vasella AT, Vasella AT. Recent insights into inhibition, structure, and mechanism of configuration retaining glycosidases. Angew Chem Int Ed Engl 1999; 38(6): 750-70.
[http://dx.doi.org/10.1002/(SICI)1521-3773(19990315)38:6<750:AID-ANIE750>3.0.CO;2-6] [PMID: 29711789]
[15]
Liu Y, Ma L, Chen WH, Wang B, Xu ZL. Synthesis of xanthone derivatives with extended π-systems as alpha-glucosidase inhibitors: Insight into the probable binding mode. Bioorg Med Chem 2007; 15(8): 2810-4.
[http://dx.doi.org/10.1016/j.bmc.2007.02.030] [PMID: 17331734]
[16]
Luo JG, Wang XB, Ma L, Kong LY. Gypsophin: A novel alpha-glucosidase inhibitory cyclic peptide from the roots of Gypsophila oldhamiana. Bioorg Med Chem Lett 2007; 17(16): 4460-3.
[http://dx.doi.org/10.1016/j.bmcl.2007.06.011] [PMID: 17587576]
[17]
Saludes JP, Lievens SC, Molinski TF. Occurrence of the alpha-glucosidase inhibitor 1,4-Dideoxy-1,4-imino-D-arabinitol and related iminopentitols in marine sponges. J Nat Prod 2007; 70(3): 436-8.
[http://dx.doi.org/10.1021/np060551o] [PMID: 17378534]
[18]
Du ZY, Liu RR, Shao WY, et al. Alpha-glucosidase inhibition of natural curcuminoids and curcumin analogs. Eur J Med Chem 2006; 41(2): 213-8.
[http://dx.doi.org/10.1016/j.ejmech.2005.10.012] [PMID: 16387392]
[19]
Campbell LK, Baker DE, Campbell RK. Miglitol: Assessment of its role in the treatment of patients with diabetes mellitus. Ann Pharmacother 2000; 34(11): 1291-301.
[http://dx.doi.org/10.1345/aph.19269] [PMID: 11098345]
[20]
Hsiao SH, Liao LH, Cheng PN, Wu TJ. Hepatotoxicity associated with acarbose therapy. Ann Pharmacother 2006; 40(1): 151-4.
[http://dx.doi.org/10.1345/aph.1G336] [PMID: 16317107]
[21]
Pathak K, Das A, Shakya A, Saikia R, Sarma H. Evaluation of anti-diabetic and anti-hyperlipidemic activity of isolated bioactive compounds of leaves of Annona reticulata Linn. Nat Prod J 2021; 11(3): 414-21.
[http://dx.doi.org/10.2174/2210315510999200511132940]
[22]
Bairy PS, Das A, Nainwal LM, et al. Design, synthesis and anti-diabetic activity of some novel xanthone derivatives targeting α-glucosidase. Bangladesh J Pharmacol 2016; 11(2): 308-18.
[http://dx.doi.org/10.3329/bjp.v11i2.25851]
[23]
Nainwal LM, Parida P, Das A, Bairy PS. Design and docking of novel series of hybrid xanthones as anticancer agent to target human DNA topoisomerase 2-alpha. Bangladesh J Pharmacol 2014; 9(2): 204-17.
[http://dx.doi.org/10.3329/bjp.v9i2.18180]
[24]
Nayak Y, Hillemane V, Daroji VK, Jayashree BS, Unnikrishnan MK. Antidiabetic activity of benzopyrone analogues in nicotinamide-streptozotocin induced type 2 diabetes in rats. ScientificWorldJournal 2014; 2014: 854267.
[http://dx.doi.org/10.1155/2014/854267] [PMID: 25548795]
[25]
Kumudhavalli MV, Jaykar B. Evaluation of Anti-diabetic activity of Costusigneus (L) leaves on STZ induced diabetic rats. Pharm Sin 2012; 3(1): 1-4.
[26]
Abeeleh ME, Ismail ZB, Khaled R, et al. Induction of diabetes mellitus in rats using intraperitoneal Streptozotocin: A comparison between 2 strains of rats. Eur J Sci Res 2009; 32: 398-402.
[27]
Ramachandran S, Rajasekaran A, Adhirajan N. In vivo and in vitro antidiabetic activity of Terminalia paniculata Bark: An Evaluation of possible phytoconstituents and mechanisms for blood glucose control in diabetes. ISRN Pharmacol 2013; 2013: 484675.
[http://dx.doi.org/10.1155/2013/484675] [PMID: 23936668]
[28]
Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18(6): 499-502.
[http://dx.doi.org/10.1093/clinchem/18.6.499] [PMID: 4337382]
[29]
Gandhi GR, Sasikumar P. Antidiabetic effect of Merremia emarginata Burm. F. in streptozotocin induced diabetic rats. Asian Pac J Trop Biomed 2012; 2(4): 281-6.
[http://dx.doi.org/10.1016/S2221-1691(12)60023-9] [PMID: 23569914]

Rights & Permissions Print Cite
Article Metrics
1
© 2024 Bentham Science Publishers | Privacy Policy